Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

Trial Profile

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2018

At a glance

  • Drugs AMG 757 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 26 Sep 2018 According to the trial design presented at the 19th World Conference on Lung Cancer, extended disease patients with ongoing clinical benefit following not more than 6 cycles of first-line platinum-based chemotherapy will be enrolled in this study.
    • 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer.
    • 06 Jun 2018 Planned End Date changed from 19 Apr 2021 to 18 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top